<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709224</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-007-025</org_study_id>
    <nct_id>NCT04709224</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia</brief_title>
  <official_title>An Open-label Study to Determine the Pharmacokinetics, Safety and Tolerability of Single Ascending Doses of a Subcutaneous Injection of Lumateperone Long-Acting Injectable (LAI) Formulation in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to determine the pharmacokinetics, safety and tolerability of&#xD;
      single ascending doses of lumateperone long-acting injectable formulation in patients with&#xD;
      schizophrenia. Patients will be enrolled in one of up to three cohorts. All patients will&#xD;
      receive oral lumateperone for 5 days, followed by a 5-day washout of oral lumateperone, then&#xD;
      followed by a single dose of lumateperone LAI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum observed plasma concentration (Cmax) of lumateperone and metabolites</measure>
    <time_frame>predose and at multiple timepoints up to 6 weeks postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time of maximum observed plasma concentration (Tmax) of lumateperone and metabolites</measure>
    <time_frame>predose and at multiple timepoints up to 6 weeks postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of lumateperone and metabolites</measure>
    <time_frame>predose and at multiple timepoints up to 6 weeks postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of lumateperone and metabolites</measure>
    <time_frame>predose and at multiple timepoints up to 6 weeks postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Terminal elimination half-life (T1/2) of lumateperone and metabolites</measure>
    <time_frame>predose and at multiple timepoints up to 6 weeks postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with treatment-emergent AEs</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in platelet count</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in white blood cell count</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aspartate aminotransferase</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in alanine aminotransferase</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in creatine kinase</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG QT Interval</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Abnormal Involuntary Movement Scale</measure>
    <time_frame>up to 6 weeks postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cohort 1: LAI Lumateperone 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: LAI Lumateperone 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: LAI Lumateperone 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumateperone Long-Acting Injectable</intervention_name>
    <description>Lumateperone Long-Acting Injectable</description>
    <arm_group_label>Cohort 1: LAI Lumateperone 50 mg</arm_group_label>
    <arm_group_label>Cohort 2: LAI Lumateperone 100 mg</arm_group_label>
    <arm_group_label>Cohort 3: LAI Lumateperone 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18 to 50 years, inclusive&#xD;
&#xD;
          -  Clinical diagnosis of schizophrenia according to Diagnostic and Statistical Manual of&#xD;
             Mental Disorders, Fifth Edition (DSM-5)&#xD;
&#xD;
          -  Clinically stable and free from acute exacerbation of psychosis for at least 3 months&#xD;
             prior to Screening per Investigator assessment&#xD;
&#xD;
          -  On a stable dose of antipsychotic medication, including lumateperone, for at least 3&#xD;
             months prior to the Screening Visit&#xD;
&#xD;
          -  Clinical Global Impression - Severity (CGI-S) score â‰¤ 3&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormality within 2 years of Screening that, in the&#xD;
             Investigator's opinion, may place the patient at risk or interfere with study outcome&#xD;
             variables&#xD;
&#xD;
          -  History of psychiatric condition other than schizophrenia that, in the Investigator's&#xD;
             opinion, may be detrimental to participation in the study&#xD;
&#xD;
          -  Any suicidal ideation within the 6 months prior to Screening, any suicidal behavior&#xD;
             within 2 years prior to Screening based on the Columbia-Suicide Severity Rating Scale&#xD;
             (C-SSRS) (excluding self-injurious, non-suicidal behavior), and/or Investigator&#xD;
             assessment that the patient is a safety risk to him/herself or others&#xD;
&#xD;
          -  Surgical or medical condition (active or chronic) that in the Investigator's opinion&#xD;
             may interfere with drug absorption, distribution, metabolism, or excretion of the&#xD;
             study drug or any other condition that may place the patient at risk; history of&#xD;
             gastric bypass or sleeve gastrectomy; history of severe dystonic reaction on&#xD;
             antipsychotics such as laryngeal spasm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ITI Clinical Trials</last_name>
    <phone>646 440-9333</phone>
    <email>ITCIClinicalTrials@itci-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

